

1 **Virtual reality as a strategy for intra-operative anxiolysis and pharmacological**
2 **sparing in patients undergoing breast surgeries: the V-RAPS randomized**
3 **controlled trial protocol**

4 Short title: The Virtual Reality for Anxiolysis and Pharmacological Sparing (V-RAPS) protocol

5 Joe Zako MD* ^{1,2}, Nicolas Daccache MD^{1,2}, Julien Burey MD^{3,4}, Ariane Clairoux, MD³, Louis Morisson
6 MD, MSc^{1,3}, Pascal Laferrière-Langlois MD, MSc ^{1,3}

7 1 Maisonneuve-Rosemont Hospital Research Center, Montreal, Quebec, Canada

8 2 Faculté de médecine, Université de Montréal

9 3 Department of Anesthesiology and Pain Medicine, Maisonneuve-Rosemont Hospital, Centre Intégré
10 Universitaire de Santé et Services Sociaux de l'Est de L'Île de Montréal, Montreal, Quebec, Canada

11 4 Department of Anesthesiology and Critical Care Medicine, Tenon Hospital, APHP Sorbonne
12 Université, Paris, France

13 * Corresponding author

14 **Email:** joe.zako@umontreal.ca (JZ)

15

16 **Funding:** This study will be funded by Dr. Pascal Laferrière-Langlois from CR-HMR and the
17 Department of Anesthesiology and Pain Medicine.

18

19 **Competing interests:** Dr PLL declares ownership interest in private companies unrelated to this work
20 (Divocco Medical and Divocco AI). Other authors declare no competing interests.

21

22 **Data availability:** Data will be made available upon request while respecting strict confidentiality.

23

24 **Protocol version 4 – October 16th, 2024**

25 **Abstract**

26 Introduction: Virtual reality (VR) has increasingly found applications beyond leisure and video games,
27 extending into the field of medicine. Recent studies indicate that VR can effectively reduce anxiety
28 and pain in pediatric patients undergoing uncomfortable medical procedures, such as burn wound
29 care. Yet, VR use in the operating room is still rare, despite a growing trend toward regional
30 anesthesia without general anesthesia; physicians still frequently rely on pharmacological sedation to
31 manage procedural anxiety. By leveraging VR's anxiolytic properties, it may be possible to decrease
32 the need for intravenous (IV) sedation which is associated with risk of adverse events like apnea and
33 hypoxemia and delayed recovery.

34 Objectives: This study's main objective is to explore the impact of VR on IV sedation requirements in
35 adult patients undergoing breast surgery under paravertebral (PV) block without general anesthesia.
36 We hypothesize that VR immersion will reduce the need for intraoperative pharmacological sedation.
37 Secondary objectives include assessing the tolerance of patients to the VR headset, examining the
38 impact of the chosen VR scenario on the primary outcome, evaluating the incidence of adverse
39 effects, measuring patient satisfaction, and analyzing the output of the Nociception Level (NOL) Index
40 among awake surgical patients.

41 Material and methods: This single center randomized controlled trial will enroll 100 patients aged 18
42 or above undergoing breast surgery under PV block. Participants will be randomly allocated to the VR
43 group or the control group; both will have access to pharmacological sedation through patient-
44 controlled sedation (PCS). Participants in the VR group will choose between three different VR
45 scenarios and will be allowed to switch between these scenarios during surgery. The primary
46 outcome will be the time-adjusted and weight adjusted dose of self-administered intraoperative
47 propofol. Secondary outcomes will include patient satisfaction, adverse events, and post-anesthesia
48 care unit length of stay (PACU LOS).

49 Ethics: This trial has been approved by the regional ethics committee (Comité d'Éthique de la
50 Recherche du CIUSSS de l'Est de l'Île de Montréal) on September 9th, 2024.

51 Trial registration: ClinicalTrials.gov (July 25th, 2024). Unique protocol ID: 2025-3802. Trial
52 identification number: NCT06522711.

53 Keywords: virtual reality, breast surgery, anxiety, pain, NOL index, patient-controlled sedation,
54 propofol

55 **1. Introduction**

56 **1.1. Background and rationale**

57 Virtual reality (VR) is a novel technology that operates through computer generated three-dimensional
58 environments with which the user can interact. These virtual experiences are accessible on various
59 interfaces, ranging from smartphone screens that display a VR environment to fully immersive
60 headsets and systems that provide haptic feedback, simulating the sense of touch (1). Over the past
61 decade, the use of VR has expanded across various medical fields. This technology has been used to
62 train residents to perform medical procedures, to allow experienced surgeons to rehearse complex
63 surgeries and has even been used as a substitute for exposure therapy when treating patients with
64 specific phobias or anxiety disorders (2-5).

65 In anesthesiology, VR immersion has been utilized during various procedures, including orthopedic
66 surgeries of the upper extremities, hip and knee arthroplasties under regional anesthesia, dental care,
67 burn wound treatment, and even during anesthesia induction (6, 7). It has shown significant potential
68 in reducing anxiety and improving patient comfort in these perioperative and periprocedural contexts,
69 although the literature on the topic mostly pertains to pediatric populations (8, 9). Notably, research
70 indicates that interactive, gamified VR scenarios provide significantly greater anxiolysis compared to
71 passive scenarios, likely due to their increased distractibility (10). While a reduction of procedural
72 anxiety has also been observed in adult populations undergoing VR immersion (11), the assessment
73 of objective outcomes, such as procedural sedative usage, has not been thoroughly explored.

74 Pharmacological sedation is a crucial part of awake medical procedures, primarily aimed at providing
75 anxiolysis and, when necessary, amnesia. However, these medications can have serious side effects,
76 such as respiratory depression, especially when used alongside opioid analgesics (12). In fact,
77 research suggests a dose-dependent relationship between the amount of procedural sedatives
78 administered and the length of recovery times in the post-anesthesia care unit (PACU) (13). This
79 highlights a critical gap in the current literature, as VR could be a low-risk adjunct or alternative to
80 procedural sedation. This is especially relevant for breast surgeries performed only under regional
81 anesthesia, which often require substantial amounts of sedatives.

82 **1.2. Objectives and hypotheses**

83 The primary objective of this study is to determine if intraoperative virtual reality immersion reduces
84 the use of self-administered propofol for patients undergoing breast surgery under paravertebral (PV)
85 block.

86 Our secondary objectives are the following:

- 87 - Appreciate the participants' initial enthusiasm at the idea of using a VR headset during
88 surgery.
- 89 - Evaluate the level of anxiety before the surgery;
- 90 - Evaluate the incidence of adverse effects such as cybersickness, nausea, bradycardia,
91 desaturation, and hypotension;
- 92 - Evaluate the time the patient spent wearing the headset;
- 93 - Evaluate the differences in sedation requirements depending on the type of VR scenario.
- 94 - Evaluate quantities of remifentanil administered;
- 95 - Evaluate quantities of ketamine administered;
- 96 - Evaluate the requirement of post-operative care and the post-anesthesia monitoring time;
- 97 - Appreciate the ease of use of the technology, enjoyment of the first scenario chosen and
98 overall satisfaction with the experience.

99 This trial also has an exploratory objective, which is to investigate the use of the Nociception Level
100 (NOL) index in awake patients undergoing surgery, and the ability to anticipate sedation self-
101 administration via the NOL index.

102 Regarding our primary objective, we hypothesize that patients undergoing breast surgery under PV
103 block with an immersive VR experience will self-administer less propofol than the control group. We
104 also hypothesize that interactive scenarios will further reduce the requirement for sedation, when
105 compared to non-interactive scenarios.

106 **1.3. Trial design**

107 This is the protocol for a prospective, minimal risk randomized controlled superiority trial conducted at
108 a single center.

109 **2. Methods**

110 This protocol follows the Standard Protocol Items: Recommendations for Interventional Trials
111 (SPIRIT) Statement guidelines (14).

112 **2.1. Participants, interventions, and outcomes**

113 **2.1.1. Study setting**

114 This trial will be conducted at Maisonneuve-Rosemont Hospital, a part of the Centre intégré
115 universitaire de santé et de services sociaux (CIUSSS) de l'est de l'île-de-Montréal (CEMTL), located
116 in Montreal, Quebec, Canada.

117 **2.1.2. Eligibility criteria**

118 We will recruit consenting adult patients undergoing elective breast surgery under PV block without
119 general anesthesia.

120 Patients will automatically be excluded from the study if they have any of the following:

- 121 1. Hearing or visual impairment;
- 122 2. History of epilepsy, seizure, or severe dizziness;
- 123 3. Severe mental impairment;
- 124 4. Recent eye or facial surgery or wounds;
- 125 5. Inability to use the VR hand controller;
- 126 6. Allergy to one of the protocolized drugs.

127 **2.1.3. Interventions**

128 Prior to entering the operating room, all participants will receive an explanation on the use of
129 intraoperative patient-controlled sedation (PCS). For those in the intervention group, a short video will
130 introduce all three VR scenarios, after which participants will select their preferred scenario, which will
131 then be documented.

132 Upon arrival in the operating room, participants will undergo standard monitoring, including non-
133 invasive blood pressure measurement, pulse-oximetry, and continuous electrocardiography using the
134 Dräger Infinity C700 monitor (Dräger Medical, Lübeck, Germany). Throughout the entire duration of
135 surgery, the NOL index finger probe, which is connected to the PMD-200 monitor (Medasense

136 Biometrics Ltd, Ramat Gan, Israel) will be applied. All intraoperative data and events will be recorded
137 on the research computer.

138 The attending anesthesiologist will perform PV block before surgery according to their usual practice.
139 Only anesthesiologists with a minimum of 10 PV blocks performed within the last year will be qualified
140 to administer this procedure to trial participants. A standardized dose of intravenous (IV) sedation will
141 be administered to all participants prior to realization of the PV block (0.15 mg/kg of propofol) and will
142 be repeated if necessary. Once the block is complete, the participant is positioned supine, and the
143 surgeon is ready for disinfection, the VR headset will be applied to those in the intervention group and
144 their chosen scenario will begin. If at any time the patient expresses a desire to discontinue VR during
145 the surgery, we will first offer them an alternate scenario. If they reiterate their willingness to stop, with
146 or without having experienced the new scenario, the headset will be removed for the remainder of the
147 surgery. In case of adverse events attributable to VR gear, such as cybersickness, discontinuation of
148 VR immersion will be at the discretion of the anesthesiologist as well as the patient. A visual
149 representation of the VR device used as well as the possible scenario choices can be seen in Fig. 1.

150 **Fig. 1** VR headset and scenario choices

151 Figure legend: **A** Paperplane Therapeutics VR headset; **B** Scenario 1 - Calm; **C** Scenario 2 - Puzzle;
152 **D** Scenario 3 - Action.

153 In both groups, the PCS protocol will consist of 0.15 mg/kg boluses of IV propofol with a lockout
154 period of 2 minutes; these parameters may be adjusted based on the lead anesthesiologist's clinical
155 judgment. For breakthrough pain, the clinician will first administer 0.5 mcg/kg of IV fentanyl and, if
156 insufficient, 0.15 mg/kg of IV ketamine. If the desired level of analgesia and sedation is not achieved
157 with these measures, the anesthesiologist will switch the participant to general anesthesia.

158 **2.1.4. Outcomes**

159 The primary outcome is the time-adjusted and weight-adjusted average or median self-administered
160 dose of propofol in mcg/kg/min.

161 Secondary outcomes include:

- 162 - Initial enthusiasm at the idea of using a VR headset during surgery assessed on a 10-point
163 Likert scale for all participants, prior to intervention allocation;
- 164 - Level of anxiety before the surgery, once allocation is confirmed and known to the patient;
- 165 - Incidence of intraoperative and postoperative adverse events such as bradycardia,
166 desaturation and hypotension as well as subjective adverse events, such as cybersickness or
167 nausea;
- 168 - Average or median total time, in minutes, during which the VR headset was worn, as well as
169 the percentage of that time relative to the overall duration of the surgery;
- 170 - Average or median total duration in minutes spent by the patient on the VR scenario chosen,
171 and the order in which VR scenarios were presented;
- 172 - Percentage of patients that switched scenarios;
- 173 - Percentage of patients that removed the headset before the end of the surgery;
- 174 - Weight-adjusted average or median administration of intraoperative IV fentanyl in mcg/kg;
- 175 - Weight-adjusted average or median administration of intraoperative IV ketamine in mg/kg;
- 176 - PACU length of stay (LOS);
- 177 - Ease of use of the technology, enjoyment of the first scenario chosen and overall satisfaction
178 with the experience assessed post-operatively on a 10-point Likert scale in the intervention
179 group only.

180 Exploratory outcome:

- 181 - NOL index readings over time per patient, assessed continuously.

182 **2.1.5. Participant timeline**

183 The research team will review the elective surgical schedule at Maisonneuve-Rosemont Hospital to
184 identify eligible patients at least one week before their surgery. After institutional consent is obtained,
185 patients' medical charts will be screened based on the study's eligibility criteria. Potential participants
186 will be contacted by telephone to explain the project and answer supplementary questions.

187 One their interest in the project is confirmed, candidates will meet with the research team on the day
188 of their surgery to address any further queries, sign the consent form, and complete the standard
189 preoperative questionnaire. After randomization, participants will undergo regional anesthesia and
190 surgery, with or without the VR headset, based on their allocation. A variety of preoperative,

191 intraoperative and postoperative assessments relating to our outcomes of interest will be performed.
192 Their involvement in the study will conclude upon discharge from the PACU. A detailed schedule of
193 enrollment, interventions, and assessments is provided in Fig. 2.

194 **Fig. 2** Schedule of enrolment, interventions and assessments

195 **2.1.6. Sample size**

196 The available literature on sedation requirements for adult patients using intraoperative VR headsets
197 during surgeries under regional anesthesia is limited and heterogeneous, with studies reporting up to
198 93% reductions in sedation requirements (15), and others reporting no significant changes (16). For
199 our sample size calculation, we estimated a 30% reduction of propofol usage in the VR group
200 compared to the control group. With a 95% confidence level and 80% power, a total of 90 patients are
201 required to achieve the desired precision for our estimate. To account for a potential dropout rate of
202 10.0%, the total sample size was increased to 100 patients.

203 **2.1.7. Recruitment**

204 Recruitment for this trial is anticipated to begin on October 30th, 2024. By screening all potential
205 candidates and contacting them by telephone beforehand, we will ensure optimal participant
206 enrolment. We expect to complete recruitment by September 2026. Experimentation and data
207 collection will also occur throughout this period.

208 **2.2. Assignment of interventions**

209 Electronic randomization of the participants will be performed by a statistician using a computer-
210 generated randomized sequence with a variable block size unknown to the investigators, and then
211 implemented in the REDCap application (Vanderbilt University) (17). Each participant's allocation will
212 be sealed in an opaque envelope and handed to the dedicated research staff not involved in patient
213 care. The envelope will be opened at the patient's entry into the operating ward, after confirming that
214 the surgery will be performed. Due to the nature of VR, the intervention cannot be blinded to
215 participants or personnel after allocation.

216 **2.3. Data collection, management and analysis**

217 **2.3.1. Data collection methods**

218 We will collect data at baseline, intraoperatively and postoperatively to assess primary and secondary
219 outcomes. Participant socio-demographic information, medical history and current medication, will be
220 collected from their medical chart. Their education level and familiarity with VR technology will also be
221 recorded through a self-reported preoperative questionnaire. Pre-operative anxiety levels will be
222 assessed using the Amsterdam Preoperative Anxiety and Information Scale (APAIS).

223 NOL index data from the PMD-200 medical monitor will be automatically collected by the device.
224 Other intraoperative events, such as propofol self-administration, as well as the use of remifentanyl or
225 ketamine, will be manually recorded. Postoperative outcomes will be collected through questionnaires
226 administered to participants prior to their discharge from the PACU, at which point we will also record
227 PACU length of stay (LOS). Adverse events of any kind will be documented when spontaneously
228 reported or observed clinically.

229 We will monitor and document the number of participants who withdraw from the study. If a participant
230 wishes to discontinue their involvement, they will be removed from the study at their request, and no
231 further data will be collected or retained after their withdrawal.

232 **2.3.2. Data management**

233 Data from this study will be collected and managed using REDCap electronic data capture tools
234 hosted at Maisonneuve-Rosemont hospital. Research staff will systematically double-check all data
235 entries for completeness and accuracy before final submission. Each participant will be assigned a
236 unique identification number upon enrollment to maintain confidentiality and ensure anonymization.

237 All collected data will be securely stored on a designated research computer, which will remain offline
238 and be located in a restricted area in Maisonneuve-Rosemont hospital. Notably, this computer will
239 utilize the integrated event-tagging system of the PMD-200 or the BetterCare software (provided by
240 Dräger, Lübeck, Germany), which is connected to the Dräger anesthesia workstation. Usage of this
241 computer will be limited to authorized research personnel, who will need encrypted logins to access
242 study data.

243 To promote data quality, double data entry will be implemented for our primary outcome. Furthermore,
244 regular, informal audits will be conducted by the research team to verify the accuracy of the study
245 data.

246 After study completion, electronic data will be retained on secure, encrypted servers for a period of 7
247 years, as per local institutional and ethical guidelines. Physical copies of patient information, such as
248 consent forms, will be securely stored in a locked file cabinet in the anesthesiology department.

249 **2.3.3. Statistical methods**

250 Descriptive statistics will be used to summarize the data by group. Primary outcome and secondary
251 continuous parameters will be presented as means with standard deviations, or medians with
252 interquartile ranges if the data is skewed or non-normally distributed. Categorical variables will be
253 reported as frequencies (%). 95% confidence intervals (CIs) for proportions or mean/median
254 differences will be presented based on the type of endpoint analyzed, and statistical significance will
255 be determined using an alpha level of 0.05. Parametric, two-sample t-tests will be performed for
256 normally distributed outcomes. Otherwise, a non-parametric Wilcoxon test will be performed.

257 Univariate analyses will be performed to explore relationships between the primary outcome and
258 other potential variables. Logistic regression will be used to analyze each independent variable's
259 association with the primary outcome. If relevant, multivariate analyses will be conducted to assess
260 the influence of additional independent variables. Subgroup analyses will also be performed to
261 explore how various factors, such as the selected VR scenario, may impact the primary and
262 secondary outcomes to address our secondary objectives. In the case of conversion to general
263 anesthesia, the participant will be considered a protocol breach for the purposes of the final statistical
264 analysis.

265 As part of our exploratory analysis, we will investigate the relationship between the NOL index and
266 propofol self-administration. Specifically, we will discretize NOL index data by qualifying what we
267 consider a spike (e.g. any score above a threshold of 50) and assess whether these spikes can
268 predict propofol self-administration timepoints.

269 All statistical analyses will be conducted using SAS, SPSS, or Python programming language with VS
270 Code or Jupyter Notebook software.

271 **2.4. Monitoring**

272 **2.4.1. Data monitoring**

273 The study is considered low-risk and will not require a formal data monitoring committee. The
274 principal investigator (PI) or designated personnel will regularly review the data on a monthly or bi-
275 weekly basis to assess study completeness, enrollment progress, protocol deviations, participant
276 dropouts, and adverse events. The study will also be continuously overseen by the regional ethics
277 committee.

278 **2.4.2. Potential harms**

279 The devices used in the study include a VR headset wirelessly paired with a tablet for broadcasting
280 immersive scenarios. These devices do not interfere with intraoperative monitoring, and the risk of
281 adverse events associated with their use is very low.

282 Any incidence of adverse effects, spontaneously reported or directly observed, will be documented
283 and assessed as part of our secondary outcomes. Participants at higher risk of serious side effects
284 will be pre-emptively screened and excluded from the study.

285 **2.4.3. Auditing**

286 There is no formal plan for auditing or inspection in this study.

287 **3. Ethics and dissemination**

288 **3.1. Research ethics approval**

289 This protocol has been approved by the regional ethics committee (Comité d'éthique en recherche du
290 CIUSSS de l'Est de l'Île de Montréal) on September 9th, 2024.

291 **3.2. Protocol amendments**

292 Any changes to the study protocol will be submitted for review by the regional ethics committee and
293 updated on ClinicalTrials.gov. These amendments will be communicated to participants and study
294 personnel where necessary and will be documented in the final study report. In the event of study
295 termination, participants will be notified, and data will be handled according to ethical guidelines.

296 **3.3. Consent or assent**

297 During recruitment, potential participants will be contacted by the research team via phone to explain
298 the project. The communication script used during these calls has been approved by the regional

299 ethics committee. Prior to surgery, the research team will meet with candidates in person to answer
300 any remaining questions. If participants wish to proceed, informed consent will be obtained and
301 signed. The form used to obtain written consent by the research staff will be made available upon
302 request to the corresponding author.

303 **3.4. Confidentiality**

304 Protected health information will not be re-used or disclosed to third parties except as required by law,
305 for authorized oversight of the research, or as permitted by patient authorization. All digital and
306 physical patient information will be stored in secure environments (see 2.3.2. Data management). All
307 team members involved in the study will receive proper training and adhere to confidentiality protocols
308 to protect participant privacy. The study will fully comply with all applicable laws, regulations, and
309 guidelines.

310 **3.5. Declaration of interests**

311 PLL declares ownership in private companies unrelated to this work (Divocco Medical and Divocco
312 AI). All other authors declare no competing interests.

313 **3.6. Access to data**

314 Only the principal investigator (PI) and co-investigators will have access to the final trial dataset.
315 Access to de-identified participant-level data can be requested from the corresponding author, while
316 ensuring strict confidentiality.

317 **3.7. Post-trial care**

318 Ensuring subject safety is a top priority for the research team and hospital staff. In the unlikely chance
319 of an unexpected serious adverse event, the PI, Dr. Pascal Laferrière-Langlois, will be immediately
320 notified and prompt actions will then be taken to provide appropriate care.

321 **3.8. Dissemination policy**

322 We aim to publish the trial results in a mid-impact factor journal in the field of anesthesia or medical
323 technology. Patients and the public were not involved in the design, conduct, or reporting of this

324 research, and will not be involved in its dissemination. Only those that contribute significantly to the
325 advancement and publication of the study will be considered eligible for authorship.

326 **4. Discussion**

327 **4.1. Limitations of study design**

328 **4.1.1. Unblinded personnel**

329 Due to the nature of VR interventions, neither the patient, the anesthesiologist or surgeon can be
330 blinded to group allocation. However, using PCS minimizes the anesthesiologist's influence on
331 propofol administration, reducing performance bias.

332 **4.1.2. Single-center study**

333 This trial will be conducted at a single hospital, which may limit the generalizability of results.
334 However, the expected sample size is larger than many similar studies, which should improve the
335 robustness and reliability of the findings.

336 **4.1.3. Short-term outcomes**

337 The study focuses solely on short-term outcomes, concluding once participants are discharged from
338 the PACU. While long-term outcomes like post-operative delirium or cognitive impairment were not
339 considered essential for this research, future studies could explore these longer-term effects.

340 **5. Author contributions**

341 Conceptualization – JZ, ND, JB, LM, PLL; Investigation – JZ, JB and PLL; Methodology – JZ, ND, JB,
342 AC, LM and PLL; Supervision – PLL; Writing (Original Draft Preparation) – JZ and JB; Writing (Review
343 & Editing) – ND, LM and PLL.

344 All authors have read and approved the final manuscript.

345 **6. Acknowledgements**

346 We thank Paperplane Therapeutics for providing the VR hardware and software. We also thank the
347 whole research team at the Laboratory of Innovative Anesthesia in Montreal (LIAM) for their
348 assistance in research organization.

349 7. References

- 350 1. Boutin J, Kmoonpuri J, Faieghi R, Chung J, de Ribaupierre S, Eagleson R. Smart haptic
351 gloves for virtual reality surgery simulation: a pilot study on external ventricular drain training.
352 *Front Robot AI*. 2023;10:1273631.
- 353 2. Carl E, Stein AT, Levihn-Coon A, Pogue JR, Rothbaum B, Emmelkamp P, et al. Virtual reality
354 exposure therapy for anxiety and related disorders: A meta-analysis of randomized controlled
355 trials. *J Anxiety Disord*. 2019;61:27-36.
- 356 3. Chumnanvej S, Chumnanvej S, Tripathi S. Assessing the benefits of digital twins in
357 neurosurgery: a systematic review. *Neurosurg Rev*. 2024;47(1):52.
- 358 4. Kuhn AW, Yu JK, Gerull KM, Silverman RM, Aleem AW. Virtual Reality and Surgical Simulation
359 Training for Orthopaedic Surgery Residents: A Qualitative Assessment of Trainee
360 Perspectives. *JB JS Open Access*. 2024;9(1).
- 361 5. Yi WS, Rouhi AD, Duffy CC, Ghanem YK, Williams NN, Dumon KR. A Systematic Review of
362 Immersive Virtual Reality for Nontechnical Skills Training in Surgery. *J Surg Educ*.
363 2024;81(1):25-36.
- 364 6. Boyce L, Jordan C, Egan T, Sivaprakasam R. Can virtual reality enhance the patient
365 experience during awake invasive procedures? A systematic review of randomized controlled
366 trials. *Pain*. 2024;165(4):741-52.
- 367 7. Hitching R, Hoffman HG, Garcia-Palacios A, Adamson MM, Madrigal E, Alhalabi W, et al. The
368 Emerging Role of Virtual Reality as an Adjunct to Procedural Sedation and Anesthesia: A
369 Narrative Review. *J Clin Med*. 2023;12(3).
- 370 8. Eijlers R, Utens E, Staals LM, de Nijs PFA, Berghmans JM, Wijnen RMH, et al. Systematic
371 Review and Meta-analysis of Virtual Reality in Pediatrics: Effects on Pain and Anxiety. *Anesth*
372 *Analg*. 2019;129(5):1344-53.
- 373 9. Wang Y, Guo L, Xiong X. Effects of Virtual Reality-Based Distraction of Pain, Fear, and Anxiety
374 During Needle-Related Procedures in Children and Adolescents. *Front Psychol*.
375 2022;13:842847.
- 376 10. Yamashita Y, Aijima R, Danjo A. Clinical effects of different virtual reality presentation content
377 on anxiety and pain: a randomized controlled trial. *Sci Rep*. 2023;13(1):20487.

- 378 11. Kodvavi MS, Asghar MA, Ghaffar RA, Nadeem I, Bhimani S, Kumari V, et al. Effectiveness of
379 virtual reality in managing pain and anxiety in adults during periprocedural period: a systematic
380 review and meta-analysis. *Langenbecks Arch Surg.* 2023;408(1):9.
- 381 12. Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. *J Emerg Med.*
382 1997;15(3):357-65.
- 383 13. Ma H, Wachtendorf LJ, Santer P, Schaefer MS, Friedrich S, Nabel S, et al. The effect of
384 intraoperative dexmedetomidine administration on length of stay in the post-anesthesia care
385 unit in ambulatory surgery: A hospital registry study. *J Clin Anesth.* 2021;72:110284.
- 386 14. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013
387 explanation and elaboration: guidance for protocols of clinical trials. *BMJ.* 2013;346:e7586.
- 388 15. Faruki AA, Nguyen TB, Gasangwa DV, Levy N, Proeschel S, Yu J, et al. Virtual reality
389 immersion compared to monitored anesthesia care for hand surgery: A randomized controlled
390 trial. *PLoS One.* 2022;17(9):e0272030.
- 391 16. Huang MY, Scharf S, Chan PY. Effects of immersive virtual reality therapy on intravenous
392 patient-controlled sedation during orthopaedic surgery under regional anesthesia: A
393 randomized controlled trial. *PLoS One.* 2020;15(2):e0229320.
- 394 17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
395 capture (REDCap)--a metadata-driven methodology and workflow process for providing
396 translational research informatics support. *J Biomed Inform.* 2009;42(2):377-81.
- 397



398 **Appendix A** World Health Organization trial registration dataset

Data category	Information
Primary Registry and Trial Identifying Number	ClinicalTrials.gov NCT06522711
Date of Registration in Primary registry	July 25 th , 2024
Secondary Identifying Numbers	Unique Protocol ID: 2025-3802
Source(s) of Monetary or Material Support	CR-HMR and the Department of Anesthesiology and Pain Medicine and Paperplane Therapeutics
Primary Sponsor	Centre intégré universitaire de santé et des services sociaux (CIUSSS) de l'est de l'île-de-Montréal (CEMTL)
Secondary Sponsor(s)	None
Contact for Public Queries	Pascal Laferrière-Langlois (pascal.laferriere-langlois@umontreal.ca)
Contact for Scientific Queries	Pascal Laferrière-Langlois (pascal.laferriere-langlois@umontreal.ca)
Public Title	The Virtual Reality for Anxiolysis and Pharmacological Sparing (V-RAPS) randomized controlled trial
Scientific Title	Virtual reality as a strategy for intra-operative anxiolysis and pharmacological sparing in patients undergoing breast surgeries: the V-RAPS randomized controlled trial
Countries of Recruitment	Canada
Health Condition(s) or Problem(s) Studied	Intraoperative anxiety and need for sedation during elective breast surgeries in adult patients
Intervention(s)	Virtual reality immersion
Key Inclusion and Exclusion Criteria	Inclusion criteria: Full consent, aged 18 years or older, undergoing elective awake breast surgery under paravertebral block Exclusion criteria: Hearing or visual impairment, history of epilepsy, seizure or severe dizziness, severe mental impairment, recent eye or facial surgery or wounds, inability to use the VR hand controller.
Study Type	Interventional, randomized, open-label, parallel, superiority study.
Date of First Enrollment	October 31 st , 2024 (Anticipated)
Sample Size	100 participants (Anticipated)
Recruitment Status	Not yet recruiting
Primary Outcome(s)	Average self-administration of propofol in mcg/kg/min

It is made available under a [CC-BY 4.0 International license](#) .

Key Secondary Outcomes	Level of anxiety before the surgery evaluated by the Amsterdam Preoperative Anxiety and Information Scale. Incidence of adverse events. Administration of remifentanyl in mcg/kg/min. Administration of ketamine in mg/kg. Total duration in minutes spent by the patient on the VR scenario chosen, and the order in which VR scenarios were presented. Post-anesthesia care unit length of stay Ease of use of the technology, enjoyment of the first scenario chosen and overall satisfaction with the experience assessed post-operatively on a 10-point Likert scale in the intervention group only.
Ethics Review	Approved by the regional ethics committee (Comité d'éthique en recherche - CIUSSS de l'Est de l'Île de Montréal) on September 9 th , 2024
Completion date	October 30 th , 2026 (Anticipated)
Summary Results	None
IPD sharing statement	Individual clinical trial participant-level data will be made available upon request to the corresponding author, while maintaining strict patient confidentiality.

399



	Pre-Allocation	Allocation	Post-allocation	Close-out
TIMEPOINT	<u>Before allocation</u>	<u>Preoperative</u>	<u>Intraoperative</u>	<u>PACU discharge</u>
<u>ENROLMENT</u>				
Eligibility screen				
Telephone outreach				
Informed consent				
Allocation through randomization				
<u>INTERVENTIONS</u>				
VR immersion				
Control				
<u>OUTCOME ASSESSMENTS</u>				
Initial enthusiasm at the idea of using VR				
Pre-operative anxiety				
Adverse events				
Scenario switches				
VR usage time				
VR gear removal				
Propofol usage				
Remifentanil usage				
Ketamine usage				
NOL index				
PACU LOS				
Patient satisfaction				